Alan Irvine, MD, DSc, shares insights on the impact of ruxolitinib on quality of life in pediatric patients and 2024 AAD research presentations to take into consideration.
Alan Irvine, MD, DSc
Advertisement
Articles by Alan Irvine, MD, DSc
Alan Irvine, MD, DSc, offers an understanding of BSA changes and anti-inflammatory effects of ruxolitinib in the latest research presented.
Alan Irvine, MD, DSc, discusses his Revolutionizing Atopic Dermatitis session and exciting advances in AD.
Advertisement
Latest Updated Articles
Assessing Quality of Life and AAD Research ConsiderationsPublished: April 12th 2024 | Updated:
- Observing BSA Changes and Inflammation Resolution
Published: April 12th 2024 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Reviewing Type 2 Inflammation Through a Different Lens
3
Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott
4
Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic
5
